What is the official website of Lilly España ?

The official website of Lilly España is https://www.lilly.es.

What is Lilly España's cybersecurity risk score?

Lilly España has an AI-generated cybersecurity risk score of 759 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Lilly España experienced?

According to Rankiteo, Lilly España currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Lilly España been affected by any supply chain cyber incidents ?

According to Rankiteo, Lilly España has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Lilly España have SOC 2 Type 1 certification ?

According to Rankiteo, Lilly España is not certified under SOC 2 Type 1.

Does Lilly España have SOC 2 Type 2 certification ?

According to Rankiteo, Lilly España does not hold a SOC 2 Type 2 certification.

Does Lilly España comply with GDPR ?

According to Rankiteo, Lilly España is not listed as GDPR compliant.

Does Lilly España have PCI DSS certification ?

According to Rankiteo, Lilly España does not currently maintain PCI DSS compliance.

Does Lilly España comply with HIPAA ?

According to Rankiteo, Lilly España is not compliant with HIPAA regulations.

Does Lilly España have ISO 27001 certification ?

According to Rankiteo,Lilly España is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Lilly España operate in ?

Lilly España operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Lilly España have ?

Lilly España employs approximately None employees people worldwide.

Does Lilly España own any subsidiaries ?

Lilly España presently has no subsidiaries across any sectors.

How many LinkedIn followers does Lilly España have ?

Lilly España's official LinkedIn profile has approximately 25,149 followers.

What is the NAICS classification code for Lilly España ?

Lilly España is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Lilly España have a Crunchbase profile ?

No, Lilly España does not have a profile on Crunchbase.

Does Lilly España have a LinkedIn profile ?

Yes, Lilly España maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/lilly-espana.

How many cybersecurity incidents has Lilly España experienced ?

As of June 16, 2026, Rankiteo reports that Lilly España has not experienced any cybersecurity incidents.

How many peer or competitor companies does Lilly España have ?

Lilly España has an estimated 5,692 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Lilly España

Boost Score +25 with badge (5 left)

759

/1000

Fair

784

/1000

Fair

Lilly España Vendor Cyber Rating & Cyber Score

lilly.es

Add Your Compliance Badge

Durante casi 150 años, hemos sido pioneros en descubrimientos que cambian la vida y, hoy en día, nuestros medicamentos ayudan a más de 47 millones de personas en todo el mundo. Aprovechando el poder de la biotecnología, la química y la genética, nuestros científicos están avanzando sin descanso en nuevos hallazgos para resolver algunos de los desafíos de salud más importantes del mundo, redefiniendo el cuidado de la diabetes, tratando la obesidad y reduciendo sus efectos más devastadores a largo plazo, avanzando en la lucha contra la enfermedad de Alzheimer, proporcionando soluciones a algunos de los trastornos del sistema inmunológico más debilitantes y transformando los tumores más difíciles de tratar en enfermedades manejables. En

Lilly España A.I CyberSecurity Scoring

Scoring History

Lilly España

Lilly España CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Lilly España Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Lilly España

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Lilly España in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Lilly España in 2026.

Incident Types Lilly España vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Lilly España in 2026.

Incident History - Lilly España (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Lilly España Subsidiaries

Lilly España

Pharmaceutical Manufacturing

Website: https://www.lilly.es

Company Size: 1,001-5,000 employees

Eli Lilly and CompanyPharmaceutical Manufacturing

Eli Lilly ItaliaPharmaceutical Manufacturing

ImClone Systems, a wholly-owned subsidiary of Eli Lilly and CompanyBiotechnology Research

Lilly IndiaPharmaceutical Manufacturing

Eli Lilly Australia & New ZealandPharmaceutical Manufacturing

Loading…

Lilly España Similar Companies

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Loading…

NEWS

Lilly España CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-53430

SUMMARY

Improper Handling of Highly Compressed Data (Data Amplification) vulnerability in elixir-grpc grpc (GRPC.Compressor.Gzip, GRPC.Message modules) allows a denial of service via a gzip decompression bomb. This vulnerability is associated with program files lib/grpc/compressor/gzip.ex, lib/grpc/message.ex and program routines 'Elixir.GRPC.Compressor.Gzip':decompress/1, 'Elixir.GRPC.Message':from_data/2. 'Elixir.GRPC.Compressor.Gzip':decompress/1 calls :zlib.gunzip/1 directly on attacker-controlled bytes with no decompressed-size limit, ratio check, or incremental decoding. Because this module is the registered gzip GRPC.Compressor implementation, it is invoked automatically whenever an incoming gRPC frame carries the grpc-encoding: gzip header. :zlib.gunzip/1 allocates the entire decompressed result as a single binary, so a small highly compressible payload (for example a few kilobytes of zeros, which gzip compresses at roughly 1000:1) expands to multiple gigabytes inside a single call. The max_receive_message_length limit is enforced only against the already-decompressed message, so it provides no protection. An unauthenticated remote peer can send a single crafted frame to exhaust the BEAM node's heap and trigger an out-of-memory kill. This issue affects grpc: from 0.4.0 before 1.0.0.

Published

Date2026-06-15

Updated

Date2026-06-15

RISK INFORMATION (Score: )

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-48854

SUMMARY

Allocation of Resources Without Limits or Throttling vulnerability in elixir-grpc grpc allows unauthenticated attackers to exhaust the BEAM's memory and crash the server by streaming a large or slow-trickle unary request body. 'Elixir.GRPC.Server.Adapters.Cowboy.Handler':read_full_body/3 (lib/grpc/server/adapters/cowboy/handler.ex) accumulates every received chunk into a single growing binary with no size cap. Additionally, when the client omits the grpc-timeout header, the per-chunk read timeout resolves to :infinity, allowing a slow-trickle client to keep the connection alive indefinitely while memory grows. A single connection is sufficient to exhaust server memory and crash the node. This issue affects grpc from 0.3.1 before 1.0.0.

Published

Date2026-06-15

Updated

Date2026-06-15

RISK INFORMATION (Score: )

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-48853

SUMMARY

Deserialization of Untrusted Data and Allocation of Resources Without Limits or Throttling vulnerabilities in elixir-grpc grpc allow unauthenticated attackers to crash the BEAM node via atom table exhaustion and, when a decoded term flows into a call site that invokes it, achieve remote code execution on the server. 'Elixir.GRPC.Codec.Erlpack':decode/2 (lib/grpc/codec/erlpack.ex) calls :erlang.binary_to_term/1 on the raw gRPC message body without the :safe option, no size bound, and no type guard. Any unauthenticated peer that sends a request with Content-Type: application/grpc+erlpack can send a crafted payload that mints arbitrary new atoms (which are never garbage-collected, exhausting the bounded atom table and crashing the VM) or that encodes a fun term which, if applied anywhere downstream, executes attacker-controlled code inside the server process. This issue affects grpc from 0.4.0 before 1.0.0.

Published

Date2026-06-15

Updated

Date2026-06-15

RISK INFORMATION (Score: )

cvss4

Base Score: 9.2

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-48723

SUMMARY

The browserstack-cypress-cli is BrowserStack's CLI which allows users to run Cypress tests on BrowserStack. Versions prior to 1.36.4 are vulnerable to OS command injection via the cypress_config_file configuration parameter. In readCypressConfigUtil.js, the loadJsFile() function constructs a shell command by interpolating the user-controlled cypress_config_filepath value into a template literal, then executes it via child_process.execSync(). Shell metacharacters in the config path (specifically " and ;) allow breaking out of the quoted argument and injecting arbitrary commands. This issue has been fixed in version 1.36.6.

Published

Date2026-06-15

Updated

Date2026-06-15

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

CVE-2026-48599

SUMMARY

Authorization Bypass Through User-Controlled Key vulnerability in elixir-grpc grpc allows authenticated attackers to access or modify resources belonging to other users by smuggling a conflicting value for any path-bound field via the query string or request body. In 'Elixir.GRPC.Server.Transcode':map_request/5 (lib/grpc/server/transcode.ex), all three clauses use Map.merge/2 with path bindings as the first argument, giving them the lowest merge precedence. A request such as GET /users/me/profile?user_id=victim (or a POST with {"user_id": "victim"} when body: "*") yields a decoded protobuf struct where the path-bound field carries the attacker-supplied value rather than the router-extracted value. Any handler that uses the path-bound field for authorization, multi-tenancy scoping, or ownership checks is silently bypassed. This issue affects grpc from 0.8.0 before 1.0.0.

Published

Date2026-06-15

Updated

Date2026-06-15

RISK INFORMATION (Score: )

cvss4

Base Score: 7.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:L/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…